Levobupivacaina Bioindustria L.I.M.

Levobupivacaine Hydrochloride, the active ingredient in Levobupivacaina Bioindustria L.I.M., is a local anesthetic (amide) presented as a sterile solution for epidural use. It provides regional nerve block for surgical and obstetric procedures. GNH USA supplies Levobupivacaina Bioindustria L.I.M. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets.

Levobupivacaina is a local anesthetic used in the epidural pathway to achieve targeted nerve blockade. - Epidural anesthesia: provides surgical anesthesia for lower body procedures. - Post‑operative analgesia: delivers prolonged pain relief after surgery. - Labor analgesia: offers effective pain control during childbirth.

Levobupivacaina may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Hypotension: transient drop in blood pressure after epidural administration. - Bradycardia: slowed heart rate in some patients. - Nausea: mild to moderate feeling of sickness. - Pruritus: itching at the injection site or generalized.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm requiring monitoring. - Central nervous system toxicity: seizures or altered mental status in overdose. - Allergic reaction: rash, urticaria, or anaphylaxis in hypersensitive individuals.

When using Levobupivacaina, clinicians should consider several safety measures. - Patient assessment: evaluate cardiovascular and respiratory status before administration. - Dose titration: use the lowest effective dose to achieve desired analgesia. - Monitoring: continuously observe blood pressure, heart rate, and oxygen saturation during epidural infusion. - Contraindications: avoid in patients with known hypersensitivity to amide local anesthetics. - Drug interactions: review concomitant medications that may potentiate cardiac effects. - Store at room temperature: keep in original packaging, protect from light and moisture.

Levobupivacaina can interact with other agents that affect cardiac conduction or central nervous system function.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may increase risk of severe arrhythmias. - CNS depressants (e.g., benzodiazepines, opioids): can potentiate central toxicity.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance bradycardia. - Calcium channel blockers: could augment hypotensive effects. - MAO inhibitors: may increase risk of serotonin syndrome when combined with certain analgesics.